Development of an Oral Anticoagulation Strategy for Permanent Artificial Lung Support

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) systems for permanent respiratory support are currently under development as an alternative to lung transplantation. Direct oral anticoagulants are a promising alternative to heparin due to their oral administration and predictable pharmacology. METHODS: The efficacy of rivaroxaban for artificial surface anticoagulation was evaluated using 3 studies that determined (1) the pharmacological behavior of 0.25, 0.5, and 1 mg/kg doses of rivaroxaban in sheep; (2) the artificial surface anticoagulation efficacy of these 3 doses compared with heparin in a short-term mini-ECMO model; and (3) the efficacy of the optimal dose from study 2 with simulated oral pharmacokinetics in an extended-duration mini-ECMO model. RESULTS: Study 1 found that sheep have a higher volume of distribution (2.2 ± 0.4 L/kg) and a shorter half-life (1.4 ± 0.1 h) for rivaroxaban than humans but a similar linear relationship between prothrombin time and rivaroxaban plasma concentration. In study 2, device survival time in the heparin group (57.5 ± 13.0 min) was most similar to the 0.5 mg/kg rivaroxaban group (51.3 ± 8.8 min; P  = 0.287). This dose was selected for study 3, and no difference was found in device survival time between heparin (6.3 ± 1.3 h) and the 0.5 mg/kg rivaroxaban infusion (6.3 ± 1.6 h; P  = 0.837). Furthermore, the calculated rivaroxaban exposure was similar to the clinically approved oral rivaroxaban doses (24-h area under the plasma concentration curve = 2074 µg h/L). CONCLUSIONS: These results demonstrate that rivaroxaban has artificial surface anticoagulation efficacy similar to that of heparin at dosages that are feasible for oral administration in humans. Future studies will evaluate rivaroxaban anticoagulation using a 10-d full-scale ovine ECMO model.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed research on therapeutic compound development relevant to leech-derived anticoagulants and antithrombotic agents. Indexed in PubMed and verified against the NCBI record.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Узнайте, как это исследование связано с клинической практикой

More peer-reviewed studies in Разработка лекарственных препаратов.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)
• In-vitro antileishmanial potential of peptide drug hirudin — Khan H et al. (2017)
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines — Garcia DA, Baglin TP, Weitz JI, Samama MM (2012)
• Direct thrombin inhibitors — Lee CJ, Ansell JE (2011)
• Updates on Use and Monitoring of Direct Thrombin Inhibitors — Navaei A et al. (2026)

Browse all ASH-analysed research →